Ready-to-Use Stable Cell Lines

AMSBIO has expanded its portfolio of stable cell lines. The new cell lines express endogenous or recombinant proteins and are available in a ready-to-use format.

Using AMSBIO stable cell lines provides an optimised solution for the manufacture of therapeutic and diagnostic protein, and for applications in drug screening, pharmacological research and toxicological studies.

The extensive portfolio of ready-to-use stable cell lines available from AMSBIO includes: Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR...) ; Ion channels (CFTR, Nav1.7, Kv1.5…) ; Cell signaling (Notch, JNK, NF-?B, ERK…) ; Phosphodiesterases (aequorin, CNGA2, PDE1B…) ; Stem cell related (LGR5, OCT4, LIN28) ; Fluorescent (GFP, RFP, CFP, YFP) ; TetR ; Luciferase ; CRE recombinase / reporter ; p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).

AMSBIO also has extensive experience in cell line development and has an excellent track record of developing demanding custom cell lines for academic, biotechnology and pharmaceutical organisations worldwide. Using a lentiviral system, AMSBIO scientists with many years of experience in cell line development will quickly establish an optimised cell line according to customer specification. All AMSBIO custom cell lines are designed specifically to meet client specification, as well as the company's own rigorous internal QC criteria, all within demanding timelines.